Trial Profile
A single center, open-label, accelerated titration, dose-escalating, phase Ι study to evaluate the safety and tolerability of IT injection GX-051, stem cell based gene therapeutics in patients with very advanced head and neck cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs GX 051 (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- Sponsors Genexine
- 29 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 05 Apr 2015 Planned End Date changed from 1 Feb 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov
- 19 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.